12:00 AM
 | 
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PEP005 topical ingenol mebutate gel: Phase III data

In the double-blind, Australian and U.S. Phase III REGION-I trial in 255 patients with AK lesions on non-head locations, 0.05% PEP005 Gel applied once daily for 2 consecutive days met the primary endpoint of proportion of patients with complete AK lesion...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >